Advancements in the Application of Nanomedicine in Alzheimer’s Disease: A Therapeutic Perspective

Puranik, Nidhi; Yadav, Dhananjay; Song, Minseok

doi:10.3390/ijms241814044

Cited by 12 publications

(2 citation statements)

References 193 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many drug discovery studies in AD have been based on the 'amyloid hypothesis' as the main cause of the disease, and led to the development of drugs that counteract the formation of Aβ peptides, e.g., α,β secretase inhibitors, which reduce the cleavage of β-amyloid precursor protein (APP) and decrease Aβ40 or Aβ42 peptide generation, both considered to be neurotoxic and thus responsible of neuronal loss [23]. Other therapies focus on the treatment of hyperphosphorylated tau protein aggregates, that are a histopathological hallmark of AD and other related tauopathies [24], or on more generic targets such as neuroinflammation and neuronal mitochondrial dysfunction [25].…”

Section: Current Therapeutic Approaches To Ndsmentioning

confidence: 99%

Essential Oil Molecules Can Break the Loop of Oxidative Stress in Neurodegenerative Diseases

Spisni,

Valerii,

Massimino

2023

Biology

View full text Add to dashboard Cite

Essential oils (EOs) are mixtures of volatile compounds, extracted from aromatic plants, with multiple activities including antioxidant and anti-inflammatory ones. EOs are complex mixtures easy to find on the market and with low costs. In this mini narrative review, we have collected the results of in vitro and in vivo studies, which tested these EOs on validated models of neurodegeneration and in particular of the two main neurodegenerative diseases (NDs) that afflict humans: Alzheimer’s and Parkinson’s. Since EO compositions can vary greatly, depending on the environmental conditions, plant cultivar, and extraction methods, we focused our attention to studies involving single EO molecules, and in particular those that have demonstrated the ability to cross the blood–brain barrier. These single EO molecules, alone or in defined mixtures, could be interesting new therapies to prevent or slow down oxidative and inflammatory processes which are common mechanisms that contribute to neuronal death in all NDs.

show abstract

Section: Current Therapeutic Approaches To Ndsmentioning

confidence: 99%

Essential Oil Molecules Can Break the Loop of Oxidative Stress in Neurodegenerative Diseases

Spisni,

Valerii,

Massimino

2023

Biology

View full text Add to dashboard Cite

show abstract

“…This enables tailored nanocarrier systems to achieve specific tissue accumulation in the brain through passive or active targeting mechanisms [ 75 ].In spite of such phenomenal characteristics when administered via the conventional route, only 5% of the dose reaches the brain while the remaining 95% accumulates in non-targeted/peripheral tissues, causing potential toxicity to the reticuloendothelial system, etc. Hence, research pipelines have tended toward exploring novel strategies to improve the delivery of nanocarriers to intricate organs, including the brain [ 76 , 77 , 78 ]. In recent years, intranasal drug delivery has surfaced as a non-invasive, safer, and efficacious alternative to traditional routes of brain targeting [ 79 ].…”

Section: Introductionmentioning

confidence: 99%

Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer’s Disease Management

Dighe,

Jog,

Momin

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Alzheimer’s disease, a progressive neurodegenerative condition, is characterized by a gradual decline in cognitive functions. Current treatment approaches primarily involve the administration of medications through oral, parenteral, and transdermal routes, aiming to improve cognitive function and alleviate symptoms. However, these treatments face limitations, such as low bioavailability and inadequate permeation. Alternative invasive methods, while explored, often entail discomfort and require specialized assistance. Therefore, the development of a non-invasive and efficient delivery system is crucial. Intranasal delivery has emerged as a potential solution, although it is constrained by the unique conditions of the nasal cavity. An innovative approach involves the use of nano-carriers based on nanotechnology for intranasal delivery. This strategy has the potential to overcome current limitations by providing enhanced bioavailability, improved permeation, effective traversal of the blood–brain barrier, extended retention within the body, and precise targeting of the brain. The comprehensive review focuses on the advancements in designing various types of nano-carriers, including polymeric nanoparticles, metal nanoparticles, lipid nanoparticles, liposomes, nanoemulsions, Quantum dots, and dendrimers. These nano-carriers are specifically tailored for the intranasal delivery of therapeutic agents aimed at combatting Alzheimer’s disease. In summary, the development and utilization of intranasal delivery systems based on nanotechnology show significant potential in surmounting the constraints of current Alzheimer’s disease treatment strategies. Nevertheless, it is essential to acknowledge regulatory as well as toxicity concerns associated with this route; meticulous consideration is required when engineering a carrier. This comprehensive review underscores the potential to revolutionize Alzheimer’s disease management and highlights the importance of addressing regulatory considerations for safe and effective implementations. Embracing this strategy could lead to substantial advancements in the field of Alzheimer’s disease treatment.

show abstract

Review on pathogenesis and treatment of Alzheimer's disease

Cai,

Liu,

Fan

2024

Developmental Dynamics

View full text Add to dashboard Cite

The rising incidence of Alzheimer's disease (AD) and the associated economic impacts has prompted a global focus in the field. In recent years, there has been a growing understanding of the pathogenic mechanisms of AD, including the aggregation of β‐amyloid, hyperphosphorylated tau, and neuroinflammation. These processes collectively lead to neurodegeneration and cognitive decline, which ultimately results in the loss of autonomy in patients. Currently, there are three main types of AD treatments: clinical tools, pharmacological treatment, and material interventions. This review provides a comprehensive analysis of the underlying etiology and pathogenesis of AD, as well as an overview of the current prevalence of AD treatments. We believe this article can help deepen our understanding of the AD mechanism, and facilitate the clinical translation of scientific research or therapies, to address this global problem of AD.

show abstract

Advancements in the Application of Nanomedicine in Alzheimer’s Disease: A Therapeutic Perspective

Cited by 12 publications

References 193 publications

Essential Oil Molecules Can Break the Loop of Oxidative Stress in Neurodegenerative Diseases

Essential Oil Molecules Can Break the Loop of Oxidative Stress in Neurodegenerative Diseases

Intranasal Drug Delivery by Nanotechnology: Advances in and Challenges for Alzheimer’s Disease Management

Review on pathogenesis and treatment of Alzheimer's disease

Contact Info

Product

Resources

About